Prognostic factors in ovarian cancer: current evidence and future prospects. The ECCO 12 Educational Book. Eur J Cancer 2003;1:127-45.A. Crijns, H. Boezen, J. Schouten, H. Arts, R. Hofstra, P. Willemse, E. de Vries, A. van der Zee, Prognostic factors in ovarian cancer: Current ...
G. et al. The benefits and harms of breast cancer screening: an independent review. Br. J. Cancer 108, 2205–2240 (2013). Article CAS PubMed PubMed Central Google Scholar Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 ...
Cancer develops as a result of changes in both genetic and epigenetic mechanisms, which lead to the activation of oncogenes and the suppression of tumor su
Screening identifies not only early stage invasive cancers that are expected to be more amenable to cure, but also pre-malignancies that can be removed and thus prevented from progressing to inva- sive lesions. Finally, precancerous lesions often spontane- ously regress, presumably in response to...
G. et al. The benefits and harms of breast cancer screening: an independent review. Br. J. Cancer 108, 2205–2240 (2013). Article CAS PubMed PubMed Central Google Scholar Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 ...
Screening for individual cancers is expensive, and in the future, it may be more efficient to use a multi-cancer test (Fig. 4) that can detect a range of cancers from a single test. Such a test would also be valuable in the triage of patients presenting with non -specific symptoms, ...
observed thatSAMD4gene is overexpressed, and this is also the first report ofSAMD4gene in drug resistance of ovarian cancer cells [68,69]. The discovery provides evidence for thatSAMD4gene is related to the development of resistance to drugs that are used in chemotherapy of ovarian cancer. ...
Early detection and diagnosis of many cancers is very challenging. Late stage detection of a cancer always leads to high mortality rates. It is imperative to develop novel and more sensitive and effective diagnosis and therapeutic methods for cancer trea
H. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin. Drug Discov. 7, 819–830 (2012). CAS PubMed Google Scholar Li, Q. et al. 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, ...
H. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin. Drug Discov. 7, 819–830 (2012). CAS PubMed Google Scholar Li, Q. et al. 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, ...